{
    "clinical_study": {
        "@rank": "87534", 
        "acronym": "RAPID-HF", 
        "arm_group": [
            {
                "arm_group_label": "Pacing off", 
                "arm_group_type": "Active Comparator", 
                "description": "In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest."
            }, 
            {
                "arm_group_label": "Pacing on", 
                "arm_group_type": "Experimental", 
                "description": "In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest."
            }
        ], 
        "brief_summary": {
            "textblock": "Determine the impact of restoring normal heart rate response during exercise and daily\n      activity in patients with heart failure and a preserved ejection fraction (HFpEF) and\n      chronotropic incompetence (CI)."
        }, 
        "brief_title": "Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure", 
        "condition": [
            "Heart Failure With a Preserved Ejection Fraction", 
            "Heart Failure, Diastolic", 
            "Chronotropic Incompetence"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Heart Failure, Diastolic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          1. Age >18 years and able to provide informed consent to enroll in the trial, or consent\n             through a legal guardian or power of attorney.\n\n          2. Previous clinical diagnosis of HF with current NYHA Class II-III symptoms\n\n          3. At least one of the following within 12 months before consent: Hospitalization for\n             decompensated HF, Acute treatment for HF with intravenous loop diuretic or\n             hemofiltration, Chronic treatment with a loop diuretic for control of HF symptoms +\n             left atrial enlargement on echocardiography\n\n          4. Left ventricular EF \u226550% within 12 months with clinical stability\n\n          5. Stable cardiac medical therapy for \u226530 days\n\n          6. Sinus rhythm\n\n          7. Chronotropic incompetence on recent (within 6 months) clinical or screening exercise\n             test, defined as heart rate reserve (HRR) <0.80\n\n          8. Meet both screening criteria on clinically-performed cardiopulmonary exercise testing\n             within 12 months. Peak VO2 \u226460% age/sex-adjusted normal value + peak respiratory\n             exchange ratio (RER) \u22651.05 One of the following: NT-proBNP \u2265400 pg/mL or NT-proBNP\n             <400 pg/mL, with rest PCWP >20 mmHg and/or >25 mmHg with exercise\n\n        Exclusion Criteria\n\n          1. Inability to exercise, or non-cardiac condition that precludes exercise testing\n\n          2. Any contraindication to a pacemaker system\n\n          3. Non-cardiac condition limiting life expectancy to less than one year\n\n          4. Significant left sided structural valve disease (>mild stenosis, >moderate\n             regurgitation)\n\n          5. Hypertrophic cardiomyopathy\n\n          6. Infiltrative or inflammatory myocardial disease (amyloid, sarcoid)\n\n          7. Pericardial disease\n\n          8. Non-group 2 pulmonary arterial hypertension\n\n          9. Chronic stable exertional angina\n\n         10. Acute coronary syndrome or revascularization within 60 days\n\n         11. Other clinically important causes of dyspnea\n\n         12. Atrial fibrillation\n\n         13. PR interval >210 msec\n\n         14. Resting heart rate (HR) > 100 bpm\n\n         15. A history of reduced ejection fraction (EF<50%)\n\n         16. Advanced chronic kidney disease (GFR < 20 ml/min/1.73m2 by modified MDRD equation)\n\n         17. Women of child bearing potential without negative pregnancy test and effective\n             contraception\n\n         18. Severe anemia (Hemoglobin <10 g/dL)\n\n         19. Severe hepatic disease\n\n         20. Complex congenital heart disease\n\n         21. Listed for cardiac transplantation\n\n         22. Other class I indications for pacing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02145351", 
            "org_study_id": "13-008306"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pacing on", 
                "description": "The Advisa DR model A2DR01 is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.", 
                "intervention_name": "Rate adaptive atrial pacing using a dual-chamber pacemaker", 
                "intervention_type": "Device", 
                "other_name": [
                    "Medtronic Advisa DR MRI pacemaker model A2DR01", 
                    "Medtronic CapSureFix MRI model 5086"
                ]
            }, 
            {
                "arm_group_label": "Pacing off", 
                "description": "The identical pacing system will be implanted, but will be set to Pacing Off.", 
                "intervention_name": "Pacemaker system will be implanted but set to Pacing Off.", 
                "intervention_type": "Device", 
                "other_name": [
                    "Medtronic Advisa DR MRI model A2DR01", 
                    "Medtronic CapSureFix MRI model 5086"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "HFpEF", 
            "Heart failure", 
            "Heart failure with preserved ejection fraction", 
            "Chronotropic incompetence"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "contact": {
                "email": "Weivoda.Peggy@mayo.edu", 
                "last_name": "Peggy Weivoda", 
                "phone": "507-255-8923"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }, 
            "investigator": [
                {
                    "last_name": "Barry Borlaug", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Margaret Redfield", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Rate-Adaptive Atrial Pacing In Diastolic Heart Failure (RAPID-HF)", 
        "other_outcome": [
            {
                "measure": "Scores on Kansas City Cardiomyopathy questionnaire (KCCQ)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "NT-proBNP Levels", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Six minute walk test distance", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Self-reported symptoms of breathlessness and fatigue during cardiopulmonary exercise testing (Borg scores)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "overall_contact": {
            "email": "Weivoda.Peggy@mayo.edu", 
            "last_name": "Peggy Weivoda", 
            "phone": "507-255-8923"
        }, 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Barry Borlaug, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Oxygen consumption (VO2) at ventilatory anaerobic threshold (VAT) as measure of exercise capacity", 
            "safety_issue": "No", 
            "time_frame": "4 weeks after pacemaker activation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02145351"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Barry Borlaug", 
            "investigator_title": "PI", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Daily activity assessed by average daily minutes active from pacemaker accelerometry", 
            "safety_issue": "No", 
            "time_frame": "4 weeks after pacemaker activation"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "collaborator": {
                "agency": "Medtronic", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}